These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12893358)

  • 61. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
    Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
    J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up.
    Akaza H; Homma Y; Usami M; Hirao Y; Tsushima T; Okada K; Yokoyama M; Ohashi Y; Aso Y;
    BJU Int; 2006 Sep; 98(3):573-9. PubMed ID: 16925756
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study.
    Potosky AL; Knopf K; Clegg LX; Albertsen PC; Stanford JL; Hamilton AS; Gilliland FD; Eley JW; Stephenson RA; Hoffman RM
    J Clin Oncol; 2001 Sep; 19(17):3750-7. PubMed ID: 11533098
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Re: Diethylstilbesterol revisited: androgen deprivation, osteoporosis an prostate cancer.
    Pitts WR
    J Urol; 2002 Jul; 168(1):201; author reply 201. PubMed ID: 12050534
    [No Abstract]   [Full Text] [Related]  

  • 66. Intensity-modulated radiation therapy (IMRT) for newly diagnosed and recurrent intracranial meningiomas: preliminary results.
    Sajja R; Barnett GH; Lee SY; Harnisch G; Stevens GH; Lee J; Suh JH
    Technol Cancer Res Treat; 2005 Dec; 4(6):675-82. PubMed ID: 16292888
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Appearance of carcinosarcoma after radiotherapy for local recurrence after radical prostatectomy. Case report and review of the literature].
    Dallinger B; Würnschimmel E
    Urologe A; 2010 Jun; 49(6):750-4. PubMed ID: 20237907
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study.
    Custer B; Longstreth WT; Phillips LE; Koepsell TD; Van Belle G
    BMC Cancer; 2006 Jun; 6():152. PubMed ID: 16759391
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Recent advances in hormonal therapy for advanced prostate cancer.
    Oottamasathien S; Crawford ED
    Oncology (Williston Park); 2003 Aug; 17(8):1047-52; discussion 1054-8. PubMed ID: 12966672
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Benign brain tumors. Meningiomas, pituitary tumors, and acoustic neuromas.
    Black PM
    Neurol Clin; 1995 Nov; 13(4):927-52. PubMed ID: 8584005
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
    Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S
    Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of androgen deprivation prior to radical prostatectomy in 375 patients.
    Tunn UW; Acar O; Goldschmidt AJ
    Urol Int; 1996; 56 Suppl 1():6-12. PubMed ID: 8776811
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength.
    Williams MB; Hernandez J; Thompson I
    J Urol; 2005 Apr; 173(4):1067-71. PubMed ID: 15758703
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Radiotherapy for atypical or malignant intracranial meningioma.
    Milosevic MF; Frost PJ; Laperriere NJ; Wong CS; Simpson WJ
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(4):817-22. PubMed ID: 8598358
    [TBL] [Abstract][Full Text] [Related]  

  • 77. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Gonadotrophin-releasing hormone agonists induce osteoporosis.
    Maillefert JF; Sibilia J; Kuntz JL; Tavernier C
    Br J Rheumatol; 1994 Dec; 33(12):1199-200. PubMed ID: 8000764
    [No Abstract]   [Full Text] [Related]  

  • 79. Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery.
    Kim M; Lee DH; Kim Rn HJ; Cho YH; Kim JH; Kwon DH
    Clin Neurol Neurosurg; 2017 Feb; 153():93-101. PubMed ID: 28081463
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
    Eulau SM; Tate DJ; Stamey TA; Bagshaw MA; Hancock SL
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):735-40. PubMed ID: 9652832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.